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CLINICAL CHALLENGE1083-8791
doi:10.101Antifungal ManagementA 48-year-old man developed right lower lobe pneumonia 14 days after a cord blood transplant for acute leu-
kemia. He had been on antibiotics for persistent fever; neutrophil count was 0; blood cultures and bronchos-
copy were negative but serum galactomannan was 0.92 (positive .0.5). He was diagnosed with Aspergillus
pneumonia and treated with voriconazole.
One week later, he is clinically improved, neutropenia has resolved, but the infiltrate on CT scan is worse.
What would you recommend?
 Change to lipid amphotericin B
 Continue with voriconazole
 Continue with voriconazole and add an echinocandin (eg, caspofungin, micafungin, anidulafungin)
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In a recent issue of the ASBMT eNEWS, readers
were presented with the above Clinical Challenge
and invited to use an online poll to recommend a course
of treatment. The reader recommendations for ther-
apy were:
 49% Continue with voriconazole
 41% Continue with voriconazole and add an
echinocandin (eg, caspofungin, micafungin, anidu-
lafungin)
 10% Change to lipid amphotericin BCOMMENTARY
Approximately half of the respondents are content
with staying the course, whereas the other half chose
to alter therapy. I presume half believe that the patient
is responding, whereas half believe that treatment
is not producing an adequate response. Generally, we
use a combination of clinical, radiographic, and
microbiologic evidence in determining response to
therapy.Whenall signals arepointing in the samedirec-
tion, the decision is simple.When the signals aremixed,
as in this case, determining response is quite difficult.
Clinical signs and symptoms are at best imprecise
indicators of response. Radiography can provide
some semiquantitative data as to an increase or decrease
in the 3-dimensional volume of the infiltrate. The/10/163-0018$36.00/0
6/j.bbmt.2008.05.011problem is that infiltrates can increase either because
of greater pathogen burden or because of an increase
in the host inflammatory response to the pathogen. In
this case, we are told that neutrophil recovery has oc-
curred. Earlier studies demonstrate that the natural
history of Aspergillus pneumonia (that eventually gets
better with antifungal therapy) is that the infiltrate
worsens during the first week and only decreases after
about 2 weeks [1,2]. Indeed, cavitation often occurs
only at time of neutrophil recovery. Immune reconsti-
tution has been a well described cause of both clinical
and radiographic worsening during treatment of
a number of infectious syndromes, and thiswas recently
noted in Aspergillosis [2].
In this case, I believe immune reconstitution is
the reason for the increase in the pulmonary infil-
trate, and continuing voriconazole is the most appro-
priate course of action. The galactomannan test was
positive when the infiltrate first appeared, and repeat-
ing the test now is potentially useful in monitoring
treatment response [3]. The galactomannan assay
converts to negativity in patients who respond, while
remaining persistently positive in those who do not.
Such a surrogate marker can be enormously useful
in determining if the fungal burden is coming under
control.
Although this patient was responding to therapy,
similar cases fail to respond. There are several reasons
for lack of response. They include drug failure (resis-
tance of the pathogen to the drug or inadequate
dose), wrong diagnosis, superinfection or coinfection
by another pathogen, or inability of the host to mount441
442 J. Wingardany protective defense. How to evaluate these various
possibilities is discussed with helpful suggestions in
two recent articles [4,5].
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University of Florida Shands Cancer Center, Gainesville,
Florida
REFERENCES
1. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and
changing characteristics of invasive pulmonary aspergillosis on
sequential thoracic computed tomography scans in patients with
neutropenia. J Clin Oncol. 2001;19:253-2459.2. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution
inflammatory syndrome in cancer patients with pulmonary asper-
gillosis recovering from neutropenia: proof of principle, descrip-
tion, and clinical and research implications. Cancer. 2007;110:
112-120.
3. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus
galactomannan antigen values strongly correlate with outcome
of invasive aspergillosis: a study of 56 patients with hematologic
cancer. Cancer. 2007;110:830-834.
4. Nucci M, Perfect JR.When primary antifungal therapy fails. Clin
Infect Dis. 2008;46(9):1426-1433.
5. Wingard JR. Learning from our failures. The antifungal treat-
ment conundrum. Clin Infect Dis. 2008 (in press).
